INTRODUCTION
Adenosine appears to be an important mediator of blood-flow autoregulation to correct an imbalance between ATP synthesis and degradation . The ability of adenosine to dilate the coronary arterioles, thus increasing energy supply, but to constrict the renal artery, thus decreasing metabolic load, is consistent with this general hypothesis (Newby, 1984) . Dipyridamole, dilazep and hexobendine are likewise coronary dilators (Kubler et al., 1970; Nott, 1970; McInnes & Parratt, 1969; Buyniski et al., 1972) whereas dipyridamole is a renal vasoconstrictor (Arend et al., 1985) . Since both the coronary dilator and renal constrictor effects of dipyridamole are reversed by adenosine receptor antagonists (Afonso, 1970; Arend et al., 1985) it has been concluded that dipyridamole acts by potentiating the effects of endogenously-generated adenosine.
Dipyridamole, dilazep and hexobendine are, at vasoactive concentrations, inhibitors of the unspecific symmetric nucleoside transporter (Kubler et al., 1970; Turnheim et al., 1978; Paterson et al., 1984) . They are, however, approximately equipotent in inhibiting influx and efflux of adenosine (Kubler et al., 1970; Kukovetz & Poch, 1971/2; Degenring et al., 1976; Schutz et al., 1981; Dobson & Schrader, 1984; Belloni et al., 1985; Meghji et al., 1985) . There is controversy, therefore, as to whether and how they can increase the concentration of adenosine at extracellular receptor sites on coronary vascular smooth muscle.
To investigate this further, mathematical models were constructed according to which ( Fig. 1) Vol. 237 Plagemann & Wohlheuter, 1980; Paterson et al., 1984) . In rat cells the inhibition by dipyridamole is mixed with K, = 3 /M and Kj' = 12 ,tM (Plagemann & Wohlheuter, 1980) . In other species, including humans, the inhibition may be competitive with a Ks in the range 10-300 nM (Hammond et al., 1981; Paterson et al., 1980; Jarvis et al., 1982; Plagemann & Wohlheuter, 1984) ; a value of 0.1 /tM is used. Dipyridamole concentrations found in plasma during pharmacological responses to the drug (0.1-10 /LM: Sollevi et al., 1984; Pedersen, 1979) (Arch & Newsholme, 1978) . Rates of adenosine formation of 2 nmol/min per g wet wt. in the normoxic state (Achterburg & De Jong, 1984) and 20 nmol/min per g wet wt. in the fullystimulated state Edlund et al., 1983) are modelled. Flow rates of perfused heart preparations from 2 to 20 ml/min per g wet wt. are used to model washout (Degenring et al., 1976; Frick & Lowenstein, 1976) . In the legends to the Figures, 1 unit of enzyme activity = 1 nmol/min.
RESULTS

Model 1: complete cellular compartmentation of adenosine forming and inactivating pathways
The simplest three-compartment model is obtained if no metabolism of adenosine to inosine or rephosphorylation to AMP occurs in the adenosine-forming cells (see Fig. 1 ). This yields an equation (see the Appendix) for the extracellular adenosine concentration:
from which competitive inhibition of the transporter by increasing concentrations of dipyridamole is predicted to cause a proportional increase in S. (Fig. 2) . Noncompetitive inhibition is also predicted to elevate S. (see Appendix eqn. 5 and Fig. 2 ). To understand these predictions it should be noted that the model also predicts increases in adenosine concentration inside the adenosine-forming cells (Fig. 2) . In fact the rates of transport of adenosine out of and into the adenosineforming cells are independent of dipyridamole concentration; the increases in intracellular and extracellular adenosine concentration exactly compensating for the changes in Km and Vmax.. The ratio of predicted intracellular to extracellular adenosine concentration is dictated (under the range of conditions modelled) largely by the proportion of total nucleoside transporter activity which is in the adenosine-forming cells (see Appendix eqn. 4). When this is 50%, the predicted adenosine concentration in the adenosine-forming cells is approximately twice that in the interstitial compartment (Fig. 2) .
The model also predicts a linear rise in interstitial adenosine concentration as the rate of adenosine formation increases provided that this is much less tha the Vmax. of the nucleotide transporter. Model 2: metabolism of adenosine inside the adenosineforming cells Increasing activities of adenosine deaminase or adenosine kinase inside the adenosine-forming cells reduce both the concentration of adenosine predicted in the absence of dipyridamole and dampen the rise due to nucleoside-transport inhibition (Fig. 3) . The effect of adenosine kinase is more dramatic owing to its low Km. The model predicts, none-the-less, that interstitial adenosine concentration is always increased by dipyridamole. This conclusion is independent of the values chosen for the inhibitor constants which do, however, dictate the concentration range over which a maximal effect is obtained. The reason for this increase is, again, the predicted rise in the adenosine concentration in the cytosol of the adenosine-forming cells. Indeed, the relationship between intracellular and interstitial adenosine concentration is the same in models 1 and 2. The difference between them is that the increase in adenosine concentration in the adenosine-forming cells no longer completely compensates for the inhibition of nucleoside effilux.
The factor by which dipyridamole is predicted to increase interstitial adenosine concentration is reduced as the proportion of total nucleoside transporter which is located in the adenosine-inactivating cells is reduced, for example from 50% to 20% (Fig. 3a, broken line) . This increases the predicted extracellular adenosine concentration in the absence of nucleoside transport inhibitor from 0.086 /,M to 0.200 ,lM but reduces the stimulation caused by a saturating concentration of dipyridamole from 6.24-fold to 4.59-fold. In the absence of any adenosine-inactivating cells, the model predicts no increase in extracellular adenosine concentration on adding dipyridamole. A similar pattern is produced by reducing the total activity ascribed to the transporter by 2-fold (Fig. 3a, dotted line) . This increases the predicted basal extracellular adenosine concentration to 0.152,lM but reduces the stimulation by dipyridamole to 3.89-fold. If the transporter is ascribed a very low activity, inactivation after transport becomes insignificant compared with metabolism in the adenosine-forming cells and dipyridamole again fails to elevate adenosine concentration.
The presence ofmetabolizing enzymes in the adenosineforming cells also reduces the extent to which interstitial adenosine concentration rises in response to an increase in adenosine formation rate (Fig. 4) . This effect is progressively overcome at higher rates especially when the metabolizing enzymes become saturated. The increase is greater when the proportion of total nucleoside transporter activity in the adenosine-inactivating cells is reduced (Fig. 4, (see the Appendix). At physiological concentrations of adenosine, however, well below the Km of adenosine deaminase and that of the transporter, approximate solutions can be obtained algebraically. Using estimates of the activities of the transporter, the kinase and the deaminase which might be expected in myocardial tissue, interstitial adenosine concentrations in the low nm range are predicted at basal levels of adenosine formation (approx. 2 nmol/min per g). These may be elevated to the utM range at adenosine formation rates of 20 nmol/min per g, corresponding to extreme hypoxia (Fig. 5) . Dipyridamole is predicted to elevate the interstitial adenosine concentration at all adenosine formation rates (Fig. 5) . Greater-fold elevations are obtained, however, at higher rates of adenosine formation. Indeed, if the rate of adenosine formation exceeds the Vmax of the metabolizing enzymes, both models 2 and 3 reduce to a form similar to model 1. Model 4: washout from the interstitial compartment Washout of adenosine from the interstitial space introduces a term into the equation for nucleoside removal which is independent of dipyridamole concentration but linearly dependent on the interstitial fluid adenosine concentration (see the Appendix). Incorporation of this term into a simplified form of model 2 allows one to assess the effects of washout on predicted adenosine concentrations. Strikingly, the adenosine concentrations inside the adenosine-forming cells are not greatly influenced by washout (Fig. 6a) . However, the interstitial adenosine concentration may be either elevated at low concentrations of dipyridamole and low rates of washout or reduced at high concentrations of dipyridamole and high rates of washout (Fig. 6b) . The predicted concentration ofdipyridamole which optimally elevates adenosine concentration is proportional to the value of the inhibitor constant used in the model, although the shape of the curves is not otherwise altered. The rate of washout of adenosine, since it is proportional to the interstitial adenosine concentration, will show a similar dependence on dipyridamole concentration and on flow rate.
DISCUSSION
Relevance of the models to the physiological processes of adenosine formation, transport and inactivation Cellular compartmentation of adenosine formation and inactivation has been demonstrated in the heart (Schrader & Gerlach, 1976; Schrader et al., 1977; Nees & Gerlach, 1983) . Thus during ischaemia or increased work-load adenosine formation takes place in the cytoplasm of the cardiac myocytes Schutz et al., 1981) probably by the action of a cytoplasmic 5'-nucleotidase (Worku & Newby, 1983; Lowenstein et al., 1983) . Using neonatal-rat heart cells in culture, Meghji et al. (1985) confirmed the cytoplasmic location of adenosine formation and demonstrated unequivocally that adenosine release occurs via the symmetric nucleoside transporter. Vascular smooth muscle and endothelial cells may be important sites of adenosine inactivation (Pearson et al., 1978) and indeed preferential incorporation of infused adenosine into these cell types occurs in the heart (Nees & Gerlach, 1983; Bassingthwaighte et al., 1985) . As pointed out by Plagemann & Wohlheuter (1980) , adenosine inactivation by cells not actively producing adenosine will at low nucleoside concentrations be limited by transport. This assumption can be tested mathematically (see the Appendix) and is valid particularly in the presence of transport inhibitors (Fig. 7) . The vascular smooth muscle adenosine receptors are located in an interstitial compartment between the cardiac myocytes and the smooth muscle and endothelial cells, and washout from this compartment may be restricted by the endothelial barrier (Bassingthwaighte et al., 1985) . Thus the mathematical models are based on the known features of adenosine formation, transport and inactivation and given reasonable estimates of the input parameters they predict interstitial fluid adenosine concentrations in the vasoactive range. Precise comparison of the predictions of the models with experimental data must await the determination of the activities and distribution ofthe adenosine transporter and of the adenosine-metabolizing enzymes in the different cell types of the heart and other adenosinesensitive tissues. Absolute rather than net rates of adenosine formation must also be measured. Implications for the action of dipyridamole
The vasodilator action of dipyridamole has been cited as evidence both for and against the adenosine hypothesis of coronary blood-flow autoregulation. Kubler et al. (1970) argued that since dipyridamole inhibited the outflow of adenosine from buffer-perfused dog hearts it must reduce adenosine efflux from cardiac The thesis that nucleoside transport would be rate-limiting for nucleoside inactivation was tested by using values of parameters in human erythrocytes, V = 4000 units/g, myocytes and hence reduce the adenosine concentration at arteriolar smooth muscle receptors. Its action thus appeared contradictory to the adenosine hypothesis. Degenring et al. (1976) argued, on the contrary, that the ability of dipyridamole to increase tissue adenosine concentration was evidence for the adenosine hypothesis. They suggested that dipyridamole selectively inhibited adenosine influx and that adenosine was, therefore, trapped by dipyridamole in an exclusively interstitial compartment. Schrader et al. (1981) and Schutz et al. (1981) showed, however, that the major portion of the adenosine accumulated in a cytoplasmic compartment containing S-adenosylhomocysteine hydrolase. Nucleoside transport inhibitors are known, also, to inhibit both nucleoside influx and efflux (see the Introduction). More recently, Knabb et al. (1984) showed in blood-perfused dog hearts that dipyridamole potentiated the accumulation of adenosine in a superfusate (pericardial infusate) which may be in equilibrium with the interstitial fluid but had no effect on coronary-sinus plasma adenosine concentration. The fixed relation between pericardial infusate adenosine concentration and coronary blood flow was cited as strong evidence in favour of the adenosine hypothesis. The models presented here reconcile these seeming inconsistencies and demonstrate how even symmetric inhibition of the nucleoside transporter can elevate both cytosolic and interstitial-fluid adenosine concentrations. Transport inhibitors will inhibit nucleoside efflux from the adenosine-forming cells but quantitatively more importantly will inhibit entry into adenosine-inactivating cells. This, descriptively, is the basis for the rise in interstitial concentration. Since the equations are written in terms of concentration, no restriction is placed on the size of the interstitial pool of adenosine which may, therefore, be small compared with the cytosolic pool. As predicted by model 4, release of adenosine into perfusates of tissues may be either increased (Wiener et al., 1983) , decreased or unaltered by nucleoside-transport inhibitors, depending on the concentration of transport inhibitor used and on the efficiency of washout of the various interstitial compartments which communicate with the vascular lumen. The only essential conditions for the coronary vasodilator effect of dipyridamole are, according to these models, that there should exist cell types close to the vascular smooth muscle adenosine receptor that inactivate but do not readily form adenosine during hypoxia or ischaemia and that the receptors must be located in an interstitial compartment, the washout from which is restricted. These predictions must now be tested further.
APPENDIX DEFINITION OF SYMBOLS
As illustrated in Fig Vol. 237
